Cardiology in Review最新文献

筛选
英文 中文
Patent Foramen Ovale in Adults With Right-to-Left Shunting: Clinical Significance, Diagnosis, and Contemporary Management. 成人卵圆孔未闭右至左分流:临床意义、诊断和当代处理。
IF 3.2 4区 医学
Cardiology in Review Pub Date : 2026-11-12 DOI: 10.1097/CRD.0000000000001493
Amy J Gagliardi, William H Frishman
{"title":"Patent Foramen Ovale in Adults With Right-to-Left Shunting: Clinical Significance, Diagnosis, and Contemporary Management.","authors":"Amy J Gagliardi, William H Frishman","doi":"10.1097/CRD.0000000000001493","DOIUrl":"https://doi.org/10.1097/CRD.0000000000001493","url":null,"abstract":"<p><p>During fetal development, the foramen ovale is an important component of normal fetal circulation, allowing oxygenated blood to bypass the nonfunctional fetal lungs and supporting fetal growth and development. After birth, incomplete fusion of the septum primum and septum secundum may result in a persistent patent foramen ovale (PFO), which is present in approximately 25% of adults. Although most individuals remain asymptomatic, PFO has been recognized as an important contributor to paradoxical embolism and cryptogenic ischemic stroke. The clinical significance of PFO depends not only on its presence, but also on patient characteristics and anatomical features that influence the likelihood of right-to-left shunting and embolic events. High-risk morphology characteristics, including a large interatrial communication, elongated tunnel length, and prominent Eustachian valve or Chiari network, are associated with increased embolic potential. Advances in multimodality imaging, particularly contrast transesophageal echocardiography, have improved the diagnosis and anatomical characterization of PFO, while risk stratification tools such as the Risk of Paradoxical Embolism (RoPE) score and the PASCAL classification are important tools when determining whether a PFO is likely to be causally related to ischemic stroke. Treatment options for PFO are also largely related to the risk and morphology of the PFO, with age and risk of recurrent strokes impacting potential treatment options. Closure of PFO may not be recommended in all patients; however, percutaneous closure has become more prevalent in recent years due to its less invasive nature.</p>","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Routine Percutaneous Coronary Intervention Versus Conservative Management in Patients Undergoing Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 经导管主动脉瓣植入术患者的常规经皮冠状动脉介入治疗与保守治疗:随机对照试验的系统回顾和荟萃分析
IF 3.2 4区 医学
Cardiology in Review Pub Date : 2026-11-10 DOI: 10.1097/CRD.0000000000001535
Ahmed Adel Mohamed, Bandar Alawlaqi, Abdullah Moemen Ahmed, Ahmed Elhadi, Ali Samir Galal, Eslam Saber Mahmoud, Ibrahim Saeed Shahda, Habiba Mostafa, Kenzy Ahmed Mohammed, Yousef Abdul-Rafea Saad, Hamzah M Alghzawi
{"title":"Routine Percutaneous Coronary Intervention Versus Conservative Management in Patients Undergoing Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","authors":"Ahmed Adel Mohamed, Bandar Alawlaqi, Abdullah Moemen Ahmed, Ahmed Elhadi, Ali Samir Galal, Eslam Saber Mahmoud, Ibrahim Saeed Shahda, Habiba Mostafa, Kenzy Ahmed Mohammed, Yousef Abdul-Rafea Saad, Hamzah M Alghzawi","doi":"10.1097/CRD.0000000000001535","DOIUrl":"https://doi.org/10.1097/CRD.0000000000001535","url":null,"abstract":"<p><p>Coronary artery disease commonly coexists with severe aortic stenosis in transcatheter aortic valve implantation (TAVI) candidates, yet optimal revascularization remains debated. We meta-analyzed randomized controlled trials comparing routine percutaneous coronary intervention (PCI) before or concomitant with TAVI versus conservative management. Major databases were searched through May 2026. Random-effects models calculated risk ratios (RRs) with 95% confidence intervals (CIs), and evidence certainty was evaluated via the Grading of Recommendations Assessment, Development and Evaluation. Three randomized controlled trials (1156 patients; PCI: n = 579, conservative: n = 577) were included. Routine PCI was not associated with significant reductions in all-cause mortality (RR, 0.90; 95% CI, 0.70-1.15; P = 0.40), cardiac death (RR, 0.74; 95% CI, 0.51-1.08; P = 0.12), myocardial infarction (RR, 0.86; 95% CI, 0.45-1.64; P = 0.64), stroke (RR, 0.70; 95% CI, 0.48-1.03; P = 0.07), or hospitalization (RR, 1.07; 95% CI, 0.87-1.32; P = 0.52). However, PCI significantly increased major bleeding (RR, 1.57; 95% CI, 1.06-2.34; P = 0.02) and any bleeding (RR, 1.77; 95% CI, 1.27-2.48; P = 0.0008), while reducing urgent and repeat revascularization. In conclusion, routine PCI before or concomitant with TAVI reduces subsequent revascularization without conferring survival or ischemic benefit, while increasing bleeding complications. Given the moderate-to-low certainty of evidence, limited cumulative sample size, and clinical heterogeneity across trials, these findings warrant cautious interpretation and favor an individualized, Heart Team-guided revascularization strategy over routine PCI.</p>","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Congenital Heart Block: Pathophysiology, Diagnosis, and Management. 先天性心脏传导阻滞:病理生理学、诊断和管理。
IF 3.2 4区 医学
Cardiology in Review Pub Date : 2026-11-10 DOI: 10.1097/CRD.0000000000001490
Anthony J Kaywood, Alishah Ahmadi, William H Frishman
{"title":"Congenital Heart Block: Pathophysiology, Diagnosis, and Management.","authors":"Anthony J Kaywood, Alishah Ahmadi, William H Frishman","doi":"10.1097/CRD.0000000000001490","DOIUrl":"https://doi.org/10.1097/CRD.0000000000001490","url":null,"abstract":"<p><p>Congenital heart block (CHB) is a rare but potentially life-threatening form of conduction disease that manifests in utero or shortly after birth, resulting from disruption of the normal electrical conduction pathway between the atria and ventricles. The severity of CHB varies depending on the degree of atrioventricular conduction impairment, ranging from first-degree atrioventricular block, characterized by prolonged conduction, to complete third-degree block, in which atrial and ventricular activity are entirely dissociated and function independently. The most common etiology is passive transplacental transfer of maternal anti-Ro/SSA and anti-La/SSB autoantibodies, most frequently in the setting of maternal systemic lupus erythematosus or Sjögren syndrome, even when the mother is clinically asymptomatic. Less commonly, CHB arises in association with structural congenital heart disease, most notably left atrial isomerism and corrected transposition of the great arteries. The clinical spectrum ranges from an incidental prenatal finding to fetal hydrops and in utero death, with third-degree CHB carrying a perinatal mortality rate of approximately 15-30%. This review integrates current evidence on the pathophysiology, maternal autoimmune contributions, diagnostic approach, and management strategies for CHB, with an emphasis on the emerging roles of fetal surveillance, pharmacologic interventions, and postnatal pacing.</p>","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular Manifestations of Lyme Disease. 莱姆病的心血管表现。
IF 3.2 4区 医学
Cardiology in Review Pub Date : 2026-11-07 DOI: 10.1097/CRD.0000000000001520
Antonis A Manolis, Theodora A Manolis, Apostolos Vouliotis, Antonis S Manolis
{"title":"Cardiovascular Manifestations of Lyme Disease.","authors":"Antonis A Manolis, Theodora A Manolis, Apostolos Vouliotis, Antonis S Manolis","doi":"10.1097/CRD.0000000000001520","DOIUrl":"https://doi.org/10.1097/CRD.0000000000001520","url":null,"abstract":"<p><p>Lyme disease is a tick-borne zoonosis caused by Borrelia burgdorferi that can involve multiple organ systems, including the cardiovascular (CV) system, noted in ~1-10% of untreated patients. This can produce atrioventricular (AV) or bundle branch block, atrial fibrillation, and myopericarditis in the acute phase, and dilated cardiomyopathy in the chronic phase. Myocardial involvement may lead to ventricular tachyarrhythmias and sudden death. AV block is reported in ~90% of cases, and in 30-60% of cases, it may necessitate cardiac pacing, at least temporarily, as most cases of high-degree AV blocks resolve with antibiotic therapy within 1 week. Occasionally, aortic dissection may occur. Although Lyme carditis, in the form of myocarditis, pericarditis, and less often endocarditis, is generally self-limited with early appropriate therapy, there is also the potential for lasting CV sequelae, such as persistent AV block (noted in 90% of cases), dilated cardiomyopathy and heart failure, and the rare occurrence of coronary artery involvement and aneurysmal changes. Patients with Lyme disease should receive oral tetracycline or penicillin, which can decrease the incidence of late-stage disease; however, some patients may fail early treatment. In cases of aseptic meningitis and radiculoneuritis, IV penicillin will be needed. As Lyme disease has now replaced syphilis as the \"Great Imitator,\" physicians should be at vigilance for the disease, especially in endemic areas, and be familiarized with the particular skin rash of erythema chronicum migrans, an expanding skin lesion with the characteristic \"bull's-eye\" appearance patch with a center of clear skin and a distinct peripheral outer erythematous ring.</p>","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RNA-Targeted Therapeutics in Cardiovascular Risk Reduction: From Gene Silencing to Precision Cardiology. 降低心血管风险的rna靶向治疗:从基因沉默到精确心脏病学。
IF 3.2 4区 医学
Cardiology in Review Pub Date : 2026-11-06 DOI: 10.1097/CRD.0000000000001533
Ali Karim, Sakan Binte Imran, Yusra Muhammad Yousuf, Duaa Asad, Zubia Hassan, Haiqa Rahman, Muskan Aamir, Tuyyab Anwer, Sumhera Fatima, Zain Ali, Farhan Karim, Siddiqa Asad, Mehnaz Ejaz Khokhar, Ziaurrahman Musafer Konar
{"title":"RNA-Targeted Therapeutics in Cardiovascular Risk Reduction: From Gene Silencing to Precision Cardiology.","authors":"Ali Karim, Sakan Binte Imran, Yusra Muhammad Yousuf, Duaa Asad, Zubia Hassan, Haiqa Rahman, Muskan Aamir, Tuyyab Anwer, Sumhera Fatima, Zain Ali, Farhan Karim, Siddiqa Asad, Mehnaz Ejaz Khokhar, Ziaurrahman Musafer Konar","doi":"10.1097/CRD.0000000000001533","DOIUrl":"https://doi.org/10.1097/CRD.0000000000001533","url":null,"abstract":"<p><p>Advances in cardiovascular prevention and treatment have substantially improved patient outcomes. However, residual cardiovascular risk remains a major clinical challenge. Traditional lipid-lowering and antihypertensive therapies, although effective, remain limited by suboptimal adherence, adverse effects, and persistent residual cardiovascular risk. RNA-targeted therapeutics have emerged as a transformative therapeutic paradigm, offering durable and highly specific gene silencing through small interfering RNA and antisense oligonucleotide platforms. This review evaluates the current evidence on RNA-targeted therapeutics for cardiovascular risk reduction, with an emphasis on their mechanisms of action, clinical efficacy, safety, and emerging therapeutic applications. A review was conducted using PubMed, Embase, Scopus, ScienceDirect, the Cochrane Library, and ClinicalTrials.gov from inception to June 2026. A total of 154 eligible studies were included and narratively synthesized by therapeutic class and molecular target. Inclisiran reduced low-density lipoprotein cholesterol by approximately 50% with twice-yearly dosing, while pooled ORION analyses suggested a reduction in major adverse cardiovascular events. Pelacarsen, olpasiran, and lepodisiran achieved 80-98% reductions in lipoprotein(a), whereas zilebesiran lowered systolic blood pressure by more than 15 mm Hg with sustained effects for up to 24 weeks. Across studies, RNA therapeutics demonstrated favorable safety profiles, with predominantly mild injection-site reactions. Although definitive cardiovascular outcome data remain unavailable for several emerging agents, RNA-targeted therapeutics represent a promising advance in precision cardiovascular medicine by providing durable, mechanism-based therapies capable of addressing important residual cardiovascular risk.</p>","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Nutritional Intervention in Adult Patients With Heart Failure: An Updated Systematic Review and Meta-Analysis. 营养干预对成年心力衰竭患者的疗效:一项最新的系统综述和荟萃分析。
IF 3.2 4区 医学
Cardiology in Review Pub Date : 2026-11-06 DOI: 10.1097/CRD.0000000000001532
Muazma Batool, Nikhil Duseja, Muhammad Salman Mustafa, Muhammad Sameer Khan, Tehreem Rasheed, Muniba Abrar, Aleena Ihtasham
{"title":"Efficacy of Nutritional Intervention in Adult Patients With Heart Failure: An Updated Systematic Review and Meta-Analysis.","authors":"Muazma Batool, Nikhil Duseja, Muhammad Salman Mustafa, Muhammad Sameer Khan, Tehreem Rasheed, Muniba Abrar, Aleena Ihtasham","doi":"10.1097/CRD.0000000000001532","DOIUrl":"https://doi.org/10.1097/CRD.0000000000001532","url":null,"abstract":"<p><p>Approximately 50% of heart failure (HF) patients are malnourished, doubling mortality risk; however, interventional evidence remains limited. A previously published meta-analysis found modest weight improvements only in malnourished/cachectic patients (5 studies, n = 275). This review updates the evidence in a broader HF population to evaluate the effect of nutritional interventions on all-cause mortality, hospital readmissions, and body mass index (BMI) in HF, determine whether intervention type moderates effect size, and identify sources of heterogeneity via meta-regression. This PRISMA-compliant, PROSPERO-registered (CRD420261445761) systematic review and meta-analysis searched PubMed, Scopus, Cochrane, and Embase for randomized controlled trials, quasi-randomized, and observational studies evaluating nutritional interventions (supplements, fortification, enteral/parenteral nutrition, counseling, with or without exercise) to increase protein/energy intake in HF, updating a 2021 search. Two reviewers independently screened, extracted data, and assessed risk of bias (RoB 2.0 for randomized controlled trials; ROBINS-I for observational studies). Random-effects models pooled risk ratios (RRs) and mean differences (MDs), with subgroup, meta-regression, and sensitivity analyses. Of 7190 records screened, 23 studies (n = 2240) were included; 18 contributed to meta-analysis. Risk of bias was predominantly low. Nutritional intervention significantly reduced all-cause mortality (RR 0.43, 95% confidence interval: 0.26-0.71, P = 0.001), with no significant effect on readmission or BMI. Exercise capacity improved significantly (6-minute walk distance mean difference 25.01, 95% confidence interval: 5.26-44.76, P = 0.013), while quality of life, creatinine, and B-type natriuretic peptide showed no significant change. Nutritional intervention was associated with reduced mortality and improved exercise capacity in HF, though effects on hospitalization, BMI, and biomarkers were nonsignificant, warranting cautious interpretation.</p>","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GLP-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease: A Review. GLP-1受体激动剂在代谢功能障碍相关脂肪变性肝病和心血管疾病中的应用综述
IF 3.2 4区 医学
Cardiology in Review Pub Date : 2026-11-03 DOI: 10.1097/CRD.0000000000001527
Sarah Rahni, Edward Lebovics, William H Frishman, Wilbert S Aronow
{"title":"GLP-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease: A Review.","authors":"Sarah Rahni, Edward Lebovics, William H Frishman, Wilbert S Aronow","doi":"10.1097/CRD.0000000000001527","DOIUrl":"https://doi.org/10.1097/CRD.0000000000001527","url":null,"abstract":"<p><p>Glucagon-like peptide-1 receptor agonists have transformed the treatment of type 2 diabetes and obesity and have more recently demonstrated clinically important effects across the cardiometabolic spectrum, including metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction-associated steatohepatitis, and atherosclerotic cardiovascular disease. Earlier cardiovascular outcome trials established reductions in major adverse cardiovascular events by way of injectable forms in patients with diabetes, while newer evidence has expanded these findings to oral semaglutide and to other patient populations. This review summarizes the hepatic, cardiovascular, and heart-failure evidence for glucagon-like peptide-1 receptor agonists-based therapies and discusses remaining clinical uncertainties and future directions.</p>","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Baroreflex Sensitivity and Exercise Training: From Molecular Mechanisms to Cardiovascular Therapeutics. 压力反射敏感性和运动训练:从分子机制到心血管治疗。
IF 3.2 4区 医学
Cardiology in Review Pub Date : 2026-11-03 DOI: 10.1097/CRD.0000000000001519
Xue-Jiao Zhou, Qian-Yu Liu, Ya-Shu Yang, Wei-Zhong Wang, Xing Tan
{"title":"Baroreflex Sensitivity and Exercise Training: From Molecular Mechanisms to Cardiovascular Therapeutics.","authors":"Xue-Jiao Zhou, Qian-Yu Liu, Ya-Shu Yang, Wei-Zhong Wang, Xing Tan","doi":"10.1097/CRD.0000000000001519","DOIUrl":"https://doi.org/10.1097/CRD.0000000000001519","url":null,"abstract":"<p><p>Maintaining stable blood pressure is essential for normal physiological function, and the baroreceptor reflex plays a pivotal role in buffering acute blood pressure variability. Reduced baroreflex sensitivity (BRS) is closely linked to the development and progression of multiple pathological processes. Moreover, enhancing BRS has been identified as a promising therapeutic approach for cardiovascular diseases. Both observational and interventional research consistently demonstrate that long-term aerobic exercise training is associated with elevated BRS, regardless of the presence of pre-existing cardiovascular diseases. Additionally, anaerobic exercise and other exercise modalities offer varying degrees of benefits across different populations. Given the well-established therapeutic effects of exercise in various cardiovascular diseases, elucidating the underlying mechanisms is of significant importance. In this review, we integrate recent findings from human and animal studies, which propose that potential mechanisms may involve exercise-induced secretion of bioactive molecules and modulation of the autonomic nervous system. This review systematically summarizes the advances in the regulation of BRS by exercise, elucidates the underlying mechanisms whereby exercise maintains blood pressure homeostasis and protects cardiovascular function, and thus provides a critical theoretical foundation for employing exercise as an interventional strategy in the prevention and treatment of cardiovascular diseases.</p>","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prior Coronary Artery Bypass Grafting and Its Impact on Lesion Complexity, Procedural Characteristics, and Outcomes in Chronic Total Occlusion Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. 既往冠状动脉旁路移植术及其对慢性全闭塞经皮冠状动脉介入治疗病变复杂性、手术特点和结果的影响:一项系统回顾和荟萃分析。
IF 3.2 4区 医学
Cardiology in Review Pub Date : 2026-11-03 DOI: 10.1097/CRD.0000000000001499
Hafsa Azam, Bakhtawara Alam, Syed Sarmad Javaid, Hira Janjua, Syeda Ushna Hasan, Rohan Lal, Rabbia Saad, Hina Shuja, Ravi Kumar Pandey, Areej Riaz, Lohana Pooja, Sajja Shamaun Kiani, Aisha Zahid, Abrarul Haq, Muhammad Nauman Shah
{"title":"Prior Coronary Artery Bypass Grafting and Its Impact on Lesion Complexity, Procedural Characteristics, and Outcomes in Chronic Total Occlusion Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.","authors":"Hafsa Azam, Bakhtawara Alam, Syed Sarmad Javaid, Hira Janjua, Syeda Ushna Hasan, Rohan Lal, Rabbia Saad, Hina Shuja, Ravi Kumar Pandey, Areej Riaz, Lohana Pooja, Sajja Shamaun Kiani, Aisha Zahid, Abrarul Haq, Muhammad Nauman Shah","doi":"10.1097/CRD.0000000000001499","DOIUrl":"https://doi.org/10.1097/CRD.0000000000001499","url":null,"abstract":"<p><p>Prior coronary artery bypass grafting (CABG) is associated with accelerated native vessel atherosclerosis and more complex chronic total occlusion (CTO) anatomy, rendering CTO-percutaneous coronary intervention (PCI) more challenging despite contemporary technical advances. We performed a systematic review and meta-analysis to compare CTO lesion characteristics, procedural demands, and in-hospital outcomes according to prior CABG status. PubMed, the Cochrane Library, and Google Scholar were systematically searched from inception through May 15, 2026, for studies comparing CTO-PCI outcomes in patients with and without prior CABG. Data were pooled using odds ratios (ORs) and standardized mean differences (SMDs). Twelve studies enrolling 47,434 patients, including 10,354 with prior CABG, were included. Compared with patients without prior CABG, those with prior CABG had higher rates of blunt stump morphology (OR 1.51 [1.42-1.61]), proximal cap ambiguity (OR 1.55 [1.45-1.66]), calcification (OR 2.49 [2.22-2.79]), vessel bending (OR 2.27 [1.27-4.05]), distal cap bifurcation (OR 1.73 [1.51-1.98]), and higher Multicenter CTO Registry of Japan scores (SMD 0.48 [0.40-0.56]). Procedural burden was greater, with higher contrast use, longer fluoroscopy time and procedure duration, and greater stent use. Technical success (OR 0.63 [0.43-0.92]) and procedural success (OR 0.60 [0.53-0.69]) were lower in the prior CABG group. In-hospital mortality (OR 2.19), myocardial infarction (OR 2.29), and contrast-induced nephropathy (OR 1.97) were higher, whereas cardiac tamponade was less frequent (OR 0.37). Prior CABG is associated with substantially greater CTO complexity, procedural burden, and in-hospital risk, underscoring the need for careful procedural planning and individualized risk stratification in this population.</p>","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thromboembolic Complications of Orthopedic Surgery. 骨科手术的血栓栓塞并发症。
IF 3.2 4区 医学
Cardiology in Review Pub Date : 2026-11-03 DOI: 10.1097/CRD.0000000000001522
Margot Richards, Mackenzie Walles, William H Frishman
{"title":"Thromboembolic Complications of Orthopedic Surgery.","authors":"Margot Richards, Mackenzie Walles, William H Frishman","doi":"10.1097/CRD.0000000000001522","DOIUrl":"https://doi.org/10.1097/CRD.0000000000001522","url":null,"abstract":"<p><p>Orthopedic surgery is a major risk factor for thromboembolic events such as deep venous thrombosis and pulmonary embolism following a variety of surgeries such as total hip and knee replacements, fracture fixations, spinal surgeries, orthopedic traumas, and arthroscopic surgeries. Many other risk factors contribute, such as age, immobilization, combined oral contraceptive medications, genetic causes, cast immobilization, tourniquet use, and comorbidities. Prophylaxis can be done through chemoprophylaxis and/or mechanoprophylaxis. Diagnosis of deep venous thrombosis is made through ultrasonography, and pulmonary embolism diagnosis is made using risk stratification and a variety of possible tests including D-dimer levels, computed tomography pulmonary angiogram, and ventilation/perfusion scans. Treatment requires using anticoagulants for a minimum of 3 months or possibly inferior vena cava filters if anticoagulation therapy is contraindicated.</p>","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书